PL176451B1 - Pochodne indolu, środek farmaceutyczny zawierający pochodne indolu i sposób wytwarzania pochodnych indolu - Google Patents

Pochodne indolu, środek farmaceutyczny zawierający pochodne indolu i sposób wytwarzania pochodnych indolu

Info

Publication number
PL176451B1
PL176451B1 PL93305554A PL30555493A PL176451B1 PL 176451 B1 PL176451 B1 PL 176451B1 PL 93305554 A PL93305554 A PL 93305554A PL 30555493 A PL30555493 A PL 30555493A PL 176451 B1 PL176451 B1 PL 176451B1
Authority
PL
Poland
Prior art keywords
group
formula
compound
ethenyl
ethyl
Prior art date
Application number
PL93305554A
Other languages
English (en)
Polish (pl)
Inventor
Alfredo Cugola
Giovanni Gavira
Simone Giacobbe
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of PL176451B1 publication Critical patent/PL176451B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
PL93305554A 1992-04-16 1993-04-15 Pochodne indolu, środek farmaceutyczny zawierający pochodne indolu i sposób wytwarzania pochodnych indolu PL176451B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929208492A GB9208492D0 (en) 1992-04-16 1992-04-16 Heterocyclic compounds
PCT/EP1993/000938 WO1993021153A1 (en) 1992-04-16 1993-04-15 Indole-2-carboxylic acid derivatives

Publications (1)

Publication Number Publication Date
PL176451B1 true PL176451B1 (pl) 1999-05-31

Family

ID=10714220

Family Applications (1)

Application Number Title Priority Date Filing Date
PL93305554A PL176451B1 (pl) 1992-04-16 1993-04-15 Pochodne indolu, środek farmaceutyczny zawierający pochodne indolu i sposób wytwarzania pochodnych indolu

Country Status (41)

Country Link
US (4) US5373018A (enExample)
EP (1) EP0568136A1 (enExample)
JP (2) JPH07505407A (enExample)
KR (1) KR100264114B1 (enExample)
CN (1) CN1042331C (enExample)
AP (1) AP480A (enExample)
AT (1) AT403917B (enExample)
AU (1) AU666927B2 (enExample)
BE (1) BE1006343A5 (enExample)
BG (1) BG62136B1 (enExample)
BR (1) BR1100323A (enExample)
CA (3) CA2094075A1 (enExample)
CH (1) CH685630A5 (enExample)
CY (1) CY2038B1 (enExample)
CZ (1) CZ285799B6 (enExample)
DK (1) DK169890B1 (enExample)
ES (1) ES2105924B1 (enExample)
FI (1) FI106198B (enExample)
FR (1) FR2690919B1 (enExample)
GB (2) GB9208492D0 (enExample)
GE (1) GEP19991704B (enExample)
GR (1) GR1001619B (enExample)
HK (1) HK95797A (enExample)
HU (2) HU217964B (enExample)
IL (1) IL105412A (enExample)
IS (1) IS3994A (enExample)
IT (1) IT1265325B1 (enExample)
LU (1) LU88248A1 (enExample)
MX (1) MX9302195A (enExample)
MY (1) MY112232A (enExample)
NO (1) NO301879B1 (enExample)
NZ (1) NZ247413A (enExample)
OA (1) OA10103A (enExample)
PL (1) PL176451B1 (enExample)
RO (1) RO113242B1 (enExample)
RU (1) RU2129544C1 (enExample)
SE (1) SE504336C2 (enExample)
SK (1) SK281941B6 (enExample)
TW (1) TW224457B (enExample)
WO (1) WO1993021153A1 (enExample)
ZA (1) ZA932642B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
WO1994027964A1 (en) * 1993-05-27 1994-12-08 Merrell Dow Pharmaceuticals Inc. 3-(indol-3-yl) propenoic acid derivatives and as nmda antagonists
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
GB9319243D0 (en) * 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
TW280819B (enExample) * 1993-11-17 1996-07-11 Sumitomo Pharma
US5563157B1 (en) * 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
AU4416197A (en) * 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
CN1139572C (zh) * 1996-09-30 2004-02-25 阿温蒂斯药物公司 Nmda(n-甲基-d-天冬氨酸)拮抗剂
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
AU749623B2 (en) * 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
RU2277096C2 (ru) * 2000-07-31 2006-05-27 ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. Средства против слабоумия, содержащие производное 2-арил-8-оксодигидропурина в качестве активного ингредиента
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
MXPA04005427A (es) * 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
PA8579701A1 (es) * 2002-08-23 2005-05-24 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa
DE10306202A1 (de) 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
JP2006526612A (ja) * 2003-06-05 2006-11-24 ファイザー・プロダクツ・インク ベータ−ラクタマーゼ阻害剤・プロドラッグ
RU2247563C1 (ru) * 2003-06-16 2005-03-10 Пятигорская государственная фармацевтическая академия Способ получения твердой лекарственной формы, содержащей глюкозамина гидрохлорид
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
NZ548212A (en) * 2003-12-29 2010-07-30 Sepracor Inc Pyrrole and pyrazole DAAO inhibitors
RU2281755C2 (ru) * 2004-04-19 2006-08-20 Пятигорская государственная фармацевтическая академия Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для ректального применения
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US8053603B2 (en) * 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
DK2816024T3 (en) 2006-03-31 2017-10-30 Sunovion Pharmaceuticals Inc CHIRALE AMINER
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
US20090099248A1 (en) * 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
MX2009012685A (es) 2007-05-31 2009-12-14 Sepracor Inc Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina.
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
JP2010235597A (ja) * 2009-03-10 2010-10-21 Santen Pharmaceut Co Ltd ４，６−ジクロロ−１ｈ−インドール−２−カルボン酸誘導体又はその塩を有効成分として含有する視神経障害の予防又は治療剤
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
SG10202102125SA (en) 2014-04-30 2021-04-29 Yufeng Tseng Use of known compounds as d-amino acid oxidase inhibitors
EP4289425A3 (en) 2016-09-14 2024-08-07 Yufeng Jane Tseng Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors
CA3067162A1 (en) 2017-06-12 2018-12-20 Glytech Llc. Composition and method for treatment or depression and psychosis in humans
CN112707874A (zh) * 2020-12-29 2021-04-27 广东中科药物研究有限公司 一种抗病毒化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010971A (en) * 1960-08-04 1961-11-28 Smith Kline French Lab Cyclopropylamine derivatives and processes for their preparation
DK500285A (da) * 1984-11-02 1986-05-03 Glaxo Group Ltd Cephalosporinantibiotika
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
PT93943A (pt) * 1989-05-05 1991-02-08 Searle & Co Processo para a preparacao de composicoes contendo compostos indole-2-carboxilato para tratamento de perturbacoes do snc
HU216787B (hu) * 1990-07-16 1999-08-30 Merrell Dow Pharmaceuticals Inc. Eljárás excitátoros aminosav-antagonista hatású indolszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity

Also Published As

Publication number Publication date
ITRM930236A0 (it) 1993-04-15
AT403917B (de) 1998-06-25
CY2038B1 (en) 1998-04-30
RU94045915A (ru) 1996-09-10
HK95797A (en) 1997-08-08
BE1006343A5 (fr) 1994-07-26
ATA75293A (de) 1997-11-15
NO943913D0 (no) 1994-10-14
GB9307808D0 (en) 1993-06-02
WO1993021153A1 (en) 1993-10-28
NO301879B1 (no) 1997-12-22
BG62136B1 (bg) 1999-03-31
CN1042331C (zh) 1999-03-03
ES2105924B1 (es) 1998-07-01
CH685630A5 (fr) 1995-08-31
US5373018A (en) 1994-12-13
SE9301241L (sv) 1993-10-17
AU3692393A (en) 1993-10-21
GEP19991704B (en) 1999-08-05
MY112232A (en) 2001-05-31
CZ285799B6 (cs) 1999-11-17
TW224457B (enExample) 1994-06-01
US5374648A (en) 1994-12-20
ZA932642B (en) 1994-01-10
JPH07505407A (ja) 1995-06-15
KR100264114B1 (ko) 2000-11-01
OA10103A (en) 1996-12-18
DK169890B1 (da) 1995-03-27
AU666927B2 (en) 1996-02-29
FR2690919A1 (fr) 1993-11-12
CN1085212A (zh) 1994-04-13
IS3994A (is) 1993-10-17
SK124194A3 (en) 1995-05-10
RU2129544C1 (ru) 1999-04-27
EP0568136A1 (en) 1993-11-03
ES2105924A1 (es) 1997-10-16
SE9301241D0 (sv) 1993-04-15
CZ254394A3 (en) 1995-07-12
FI106198B (fi) 2000-12-15
GB2266091A (en) 1993-10-20
US5510367A (en) 1996-04-23
ITRM930236A1 (it) 1994-10-15
DK43193A (da) 1993-10-17
NZ247413A (en) 1995-12-21
DK43193D0 (da) 1993-04-15
MX9302195A (es) 1994-03-31
FI944800L (fi) 1994-10-12
RO113242B1 (ro) 1998-05-29
AP480A (en) 1996-03-22
CA2094075A1 (en) 1993-10-17
HUT70526A (en) 1995-10-30
IT1265325B1 (it) 1996-10-31
CA2094073A1 (en) 1993-10-17
IL105412A0 (en) 1993-08-18
JPH0649027A (ja) 1994-02-22
SK281941B6 (sk) 2001-09-11
CA2094076A1 (en) 1993-10-17
IL105412A (en) 1998-02-22
GB2266091B (en) 1995-08-09
SE504336C2 (sv) 1997-01-13
GR1001619B (el) 1994-07-29
BG99111A (bg) 1995-05-31
HU211826A9 (en) 1995-12-28
GB9208492D0 (en) 1992-06-03
FR2690919B1 (fr) 1995-05-05
US5374649A (en) 1994-12-20
NO943913L (no) 1994-12-14
BR1100323A (pt) 2000-06-27
LU88248A1 (fr) 1994-03-01
HU9402975D0 (en) 1995-02-28
FI944800A0 (fi) 1994-10-12
HU217964B (hu) 2000-05-28
AP9300524A0 (en) 1993-04-30

Similar Documents

Publication Publication Date Title
US5374648A (en) Indole derivatives and pharmaceutical use thereof
US5686461A (en) Indole derivatives
US5962496A (en) Indole derivatives as NMDA antagonists
US6124285A (en) Indole-2,3-dione-3-oxime derivatives
PL194532B1 (pl) Pochodne tetrahydrochinoliny jako antagoniści EAA
US5919811A (en) 3-Substituted-indole-2-carboxylic acid derivatives as excitatory amino acid antagonists
US5977136A (en) Tetrahydroquinolines as NMDA antagonists
KR20080063755A (ko) 염증성 장애 치료용 피리미딘 화합물
AU731394B2 (en) Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
EP0519353B1 (en) Indolizin derivatives, process for their preparation and pharmaceutical composition containing them